Erasca reports Q4 2025 net loss $29.1M; ERAS-0015 shows early partial responses

Erasca, Inc.

Net loss per share $(0.10) for Q4 2025 vs. $(0.11) in Q4 2024; full-year net loss $124.5M ($0.44/share).
Cash, equivalents, and marketable securities $341.8M at Dec 31, 2025; pro forma $434M after Jan 2026 $259M upsized financing.
ERAS-0015 showed confirmed partial responses across multiple RAS-mutant tumors at 8 mg QD with favorable safety and PK.
R&D expenses $23.2M in Q4, down from $26.1M YoY; total R&D $92.9M for FY 2025 vs $115.4M in FY 2024.
Expanded ERAS-0015 license to worldwide rights; composition of matter patents issued for ERAS-0015 and ERAS-4001.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Erasca, Inc. reported Q4 2025 results: net income -29.1 million, EPS -0.10.

Period: Q4 2025
Net income: -29.1 million
EPS: -0.10
Result: reported results

Exact text from the filing

Net loss was $29.1 million, or $(0.10) per basic and diluted share, for the quarter ended December 31, 2025

View on SEC.gov

Browse all earnings releases →

Erasca, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-104105

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.